Perspective Therapeutics to Present at the World Molecular Imaging Congress 2023
RICHLAND, WASH. & CORALVILLE, IOWA, Aug. 30, 2023 (GLOBE NEWSWIRE) -- (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), today announced that it will have two presentations at the upcoming World Molecular Imaging Congress (WMIC) 2023, hosted by the World Molecular Imaging Society (WMIS). The conference is being held in Prague, Czech Republic, from September 5-9, 2023.
“We are pleased with our team’s progress in pioneering the development of promising image-guided, lead-based, alpha particle therapies.” said Thijs Spoor, Chief Executive Officer at Perspective Therapeutics. “Our team continues to deepen our pipeline with exceptional data from our novel radioligand, [203/212Pb]PSC-PEG3-Adma, for image-guided pre-targeted alpha particle therapy; and our preclinical data for our lead-based alpha particle therapy, [212Pb]VMT-α-NET, continues to support ongoing clinical studies in India and our planned U.S.-based studies. We expect to provide preliminary clinical results this quarter. “
“We are excited to present some of our latest data collected in collaboration with our partner and lead author Dr. Dongyoul Lee PhD (Assistant Professor, Korea Military Academy) highlighting [212Pb]VMT-α-NET and its efficacy in the treatment of neuroendocrine tumors and the image-guided approach using imaging surrogate [203Pb]VMT-α-NET. We demonstrated the significant therapeutic benefit of [212Pb]VMT-α-NET in a mouse model and the potential for high probability of complete response.” commented Michael K. Schultz, Ph.D., Chief Scientific Officer at Perspective Therapeutics. “Furthermore, we are excited to be collaborating with our partner Jacob Houghton PhD (Assistant Professor, Radiology at Stony Brook University) to showcase a novel and game-changing guest/host platform for effective in vivo image-guided pre-targeted alpha particle therapy. Radioligand [203Pb]PSC-PEG3-Adma demonstrated extended lag times, impressive tumor-to-tissue ratios and with our ongoing efforts using a PSC chelator, we have the potential to further reduce radiation toxicity during therapy using the elementally identical therapeutic ligand [203Pb]PSC-PEG3-Adma as a guide.”
Presentation One:
Title: Targeted Alpha Therapy for Neuroendocrine Tumors: Therapeutic Efficacy and Dosimetry Analysis of [212Pb]VMT-α-NET in Preclinical Models
Summary: This presentation highlights the potential for lead-based targeted alpha particle therapy, using [212Pb]VMT-α-NET, in effectively treating neuroendocrine tumors. In a tumor xenograft mouse model, treatment with fractionated dosing of 212Pb-VMT-α-NET resulted in 70% complete response and an 80% survival rate at 120 days.
Abstract ID: 131
Session: Radiotheranostics: Probe Development and Beyond, Oncology
Presenter: Michael K. Schultz, Ph.D., chief scientific officer, Perspective Therapeutics on behalf of Major Dr. Dongyoul Lee PhD, Assistant Professor, Korean Military Academy, Seoul, South Korea.
Date and Time: Thursday, September 7, 2023, 11:00 a.m. CEST
Location: Panorama Hall
Presentation Two:
Title: Cucurbit[7]uril-adamantane host:guest pretargeting with 203Pb-labeled radioligands in xenograft models
Summary: In this presentation, favorable radiochemical and in vivo characteristics of novel radioligand [203Pb]PSC-PEG3-Adma is described for image-guided alpha-particle therapy. Synthesized with exceptional yield and purity, the radioligand demonstrated rapid and preferential tumor accumulation and lag time longer than other radioligands in development.
Session: Opening Reception and Poster Session 1: Preclinical Imaging
Presenter: Amritjyot Kaur, Ph.D.
Date and Time: Wednesday, September 6, 2023, 5:30 p.m. – 7:30 p.m. CEST
Location: Exhibit Hall
Details about the presentations can be found on the WMIC website (). Additionally, a copy of the abstracts will be available on the Publications page of the Perspective Therapeutics website following the conference.
About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a medical technology and radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body. The Company is the sole producer of Cesium-131 brachytherapy seeds and has a proprietary technology that utilizes the isotope Lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This “theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.
The Company’s melanoma (VMT-01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary lead-212 generator to secure isotope supply for clinical trial and commercial operations.
For more information, please visit the Company’s website at
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “estimate,” “believe,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company’s clinical development plans and the expected timing thereof; the expected timing for availability and release of data; the potential functionality, capabilities, and benefits of the Company’s product candidates; the Company’s expectations, beliefs, intentions, and strategies regarding the future; the Company’s intentions to improve important aspects of care in cancer treatment; and other statements that are not historical fact.
The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company’s actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation, the potential that regulatory authorities may not grant or may delay approval for the Company’s product candidates; uncertainties and delays relating to the design, enrollment, completion, and results of clinical trials; unanticipated costs and expenses; pre-clinical and early clinical trials may not be indicative of the results in later clinical trials; clinical trial results may not support regulatory approval or further development in a specified indication or at all; actions or advice of regulatory authorities may affect the design, initiation, timing, continuation and/or progress of clinical trials or result in the need for additional clinical trials; the Company’s ability to obtain and maintain regulatory approval for the Company’s product candidates; delays, interruptions or failures in the manufacture and supply of the Company’s product candidates; the size and growth potential of the markets for the Company’s product candidates, and the Company’s ability to service those markets; the Company’s cash and cash equivalents may not be sufficient to support its operating plan for as long as anticipated; the Company’s expectations, projections and estimates regarding expenses, future revenue, capital requirements, and the availability of and the need for additional financing; the Company’s ability to obtain additional funding to support its clinical development programs; the availability or potential availability of alternative products or treatments for conditions targeted by the Company that could affect the availability or commercial potential of its product candidates; the ability of the Company to manage growth and successfully integrate its businesses; the Company’s ability to maintain its key employees; sufficient training and use of the Company’s products and product candidates; the market acceptance and recognition of the Company’s products and product candidates; the Company’s ability to maintain and enforce its intellectual property rights; the Company’s ability to maintain its therapeutic isotope supply agreement with the Department of Energy; the Company’s ability to continue to comply with the procedures and regulatory requirements mandated by the FDA for additional trials, Phase 1 and 2 approvals, Fast Track approvals, and 510(k) approval and reimbursement codes; and any changes in applicable laws and regulations. Other factors that may cause the Company’s actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading “Risk Factors” in the Company’s most recent Transition Report on Form 10-KT and the Company’s most recent Quarterly Report on Form 10-Q, each filed with the Securities and Exchange Commission (the “SEC”), in the Company’s other filings with the SEC, and in the Company’s future reports to be filed with the SEC and available at .
Forward-looking statements contained in this press release are made as of this date, and the Company undertakes no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.
Investor Relations Contact: LifeSci Advisors Chuck Padala E:
